Appendix B: Sources of evidence considered by the Committee

Appendix B: Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by the Peninsula Technology Assessment Group (PenTAG):

  • Hoyle M, Rogers G, Garside R et al. The clinical and cost-effectiveness of lenalidomide for multiple myeloma in people who have received at least one prior therapy: an evidence review of the submission from Celgene, September 2008

B. The following organisations accepted the invitation to participate in this appraisal. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II, III and IV had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsor:

  • Celgene

II) Professional/specialist and patient/carer groups:

  • Leukaemia CARE

  • Leukaemia Research Fund

  • Macmillan Cancer Support

  • Myeloma UK

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians, Medical Oncology Joint Special Committee

  • Royal College of Radiologists

  • UK Myeloma Forum

III) Other consultees

  • Department of Health

  • Rotherham Primary Care Trust

  • Sandwell Primary Care Trust

  • Welsh Assembly Government

IV) Commentator organisations (did not provide written evidence and without the right of appeal)

  • Celgene/Pharmion

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • GlaxoSmithKline

  • Janssen-Cilag

  • MRC Clinical Trials Unit

  • National Collaborating Centre for Cancer

  • National Coordinating Centre for Health Technology Assessment

  • NHS Quality Improvement Scotland

  • Peninsula Technology Assessment Group

  • Pfizer

  • Schering-Plough

C. The following individuals were selected from clinical specialist and patient advocate nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on lenalidomide by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Mr Michael Brown, nominated by Myeloma UK – patient expert

  • Dr Jamie Cavenagh, Consultant Haematologist, Barts and the London NHS Trust, nominated by the UK Myeloma Forum –clinical specialist

  • Mr Eric Low, Chief Executive, Myeloma UK, nominated by Myeloma UK – patient expert

  • Dr Steve Schey, Consultant Haematologist, Kings College Hospital, nominated by National Cancer Research Institute (NCRI)/Royal College of Physicians (RCP)/Royal College of Radiologists(RCR)/Association of Cancer Physicians (ACP)/ Joint Collegiate Council on Oncology (JCCO) – clinical specialist

  • National Institute for Health and Care Excellence (NICE)